Emyria (ASX:EMD) reported a reduction in the symptoms of patients diagnosed with post-traumatic stress disorder (PTSD) who underwent its therapy program, according to a Tuesday filing with the Australian bourse.
The program showed an average reduction of 29.6 points in PCL-5 scores, which are used in assessing PTSD severity, per the filing.
Additionally, a scale measuring patients' quality of life improved by an average of 23.5 points under the program.
The results are based on an interim analysis of the first eight patients who completed Emyria's MDMA-assisted therapy for PTSD.
Emyria's shares were up nearly 3% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.